NASDAQ:CRMDCorMedix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.12 -0.26 (-5.94 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$3.94Now: $4.12▼$4.4050-Day Range$4.19MA: $5.70▼$6.5652-Week Range$2.16Now: $4.12▼$8.77Volume916,118 shsAverage Volume284,409 shsMarket Capitalization$107.64 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for CorMedix. Previous Next 2.2 Community Rank Outperform VotesCorMedix has received 40 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCorMedix has received 49 “underperform” votes. (Add your “underperform” vote.)Community SentimentCorMedix has received 55.06% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote “Outperform” if you believe CRMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRMD Previous Symbol CUSIPN/A CIK1410098 Webwww.cormedix.com Phone908-517-9500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares26,127,000Market Cap$107.64 million Next Earnings Date8/11/2020 (Estimated) OptionableOptionable $4.12 -0.26 (-5.94 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRMD News and Ratings via Email Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. CorMedix (NASDAQ:CRMD) Frequently Asked Questions How has CorMedix's stock been impacted by COVID-19 (Coronavirus)? CorMedix's stock was trading at $5.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRMD shares have decreased by 17.9% and is now trading at $4.12. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CorMedix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CorMedix. When is CorMedix's next earnings date? CorMedix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for CorMedix. How were CorMedix's earnings last quarter? CorMedix Inc (NASDAQ:CRMD) issued its earnings results on Monday, May, 11th. The company reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The firm earned $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. View CorMedix's earnings history. Has CorMedix been receiving favorable news coverage? News stories about CRMD stock have been trending very positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CorMedix earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about CorMedix. Who are some of CorMedix's key competitors? Some companies that are related to CorMedix include CEL-SCI (CVM), Biotest (BIO), Ibio (IBIO), Neptune Wellness Solutions (NEPT), Inventiva (IVA), IMV (IMV), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Tiziana Life Sciences (TILS), Synairgen (SNG), ProMetic Life Sciences (PLI), IMV (IMV), Fennec Pharmaceuticals (FRX) and Rafael (RFL). View all competitors. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), Crispr Therapeutics (CRSP), Gigamon (GIMO), Vaxart (VXRT) and Aduro BioTech (ADRO). Who are CorMedix's key executives? CorMedix's management team includes the following people: Mr. Khoso Baluch, CEO & Director (Age 60)Mr. Robert W. Cook, Chief Financial Officer (Age 62)Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance What is CorMedix's stock symbol? CorMedix trades on the NASDAQ under the ticker symbol "CRMD." How do I buy shares of CorMedix? Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CorMedix's stock price today? One share of CRMD stock can currently be purchased for approximately $4.12. How big of a company is CorMedix? CorMedix has a market capitalization of $107.64 million. What is CorMedix's official website? The official website for CorMedix is www.cormedix.com. How can I contact CorMedix? The company can be reached via phone at 908-517-9500. This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
